amr industry alliance

uniting to act on antimicrobial resistance

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.

read more

We drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:

Invest in R&D to meet public health needs with new innovative diagnostics & treatments
Improve access to high-quality antibiotics and ensuring that new ones are available to all
Work to reduce the development of antimicrobial resistance
Support measures to reduce environmental impact from production of antibiotics

shared goals

We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.

progress report

We are working on our first progress report that will be published in January 2018. This report will serve to benchmark our progress, set targets for the future and identify gaps where further efforts may be required. Stay tuned!

in action

Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.

latest news


Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come

The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches its first progress report today. The re...

Read more

New Alliance to Drive and Measure Industry Progress to Curb Antimicrobial Resistance

New Industry Alliance brings together research-based pharmaceutical companies, generics, biotech and diagnostic companies, to drive and measure industry progress to curb antimicrobial resistance....

Read more

AMR Roadmap Launched

Leading Pharmaceutical Companies Present Industry Roadmap to Combat Antimicrobial Resistance Comprehensive roadmap lays out key commitments the pharmaceutical companies pledge to deliver by 2020...

Read more

amr in numbers

AMR Impact

Life-sciences at the forefront of the battle against AMR

Development of National Action Plans




from the blog

Posted on 13/02/2018
By Gary M. Cohen, Executive Vice President of Global Health and President of the BD Foundation

Antimicrobial resistance is a growing health challenge

This blog was first published on NJToday on 5 February 2018. The growing global public health challenge of Antimicrobial Resistance (AMR) cannot be understated.  By 2050, it is a predicted to account for 10 million deaths annually, more deaths than cancer is responsible for today. The World H...

Read more view all

stay informed

Subscribe to receive our updates